What's next for Ebos after the end of that Chemist Warehouse contract

What's next for Ebos after the end of that Chemist Warehouse contract
CEO John Cullity says there isn't double-digit growth to be found in animal or healthcare in Australasia. (Image: Ebos)
Rebecca Stevenson
Ebos chief executive John Cullity says the firm must hunt outside of Australasia for double-digit growth. The dual-listed healthcare and pharmaceutical marketer and wholesaler was looking for growth outside its traditional powerhouse pharmaceutical business, Cullity said. He said Ebos’s pharmacy business in NZ and Australia was solid and stable but had relatively low growth. “Double-digit growth rates are going to be very hard, so we need to broaden the group's base of earnings outside of Australia and New Zealand...

More Markets

Warehouse drops guidance, loss now in scope
Retail

Warehouse drops guidance, loss now in scope

The retailer has raised the possibility of a full-year earnings loss.

Xero’s Melio ‘leap of faith’
Markets Analysis

Xero’s Melio ‘leap of faith’

The NZ-founded company’s giant-killer dreams in the US hinge on this huge bet. 

NZX ends half year down 3.6%
Markets Market Close

NZX ends half year down 3.6%

"We’ve continued to lag relative to other markets," analyst says.

Gregor Thompson 30 Jun 2025